公开(公告)号：US11776664B2

公开(公告)日：2023-10-03

申请号：US16952566

申请日：2020-11-19

申请人： Genomic Health, Inc.

发明人： Wayne Cowens ,  Steven Shak ,  Audrey Goddard ,  Dejan Knezevic ,  Joffre Baker ,  Michael C. Kiefer ,  Tara Maddala ,  Frederick L. Baehner

IPC分类号： G01N33/574 ,  G16B99/00 ,  G16B25/10 ,  G06N7/01

CPC分类号： G16B99/00 ,  G01N33/57438 ,  G06N7/01 ,  G16B25/10 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.

公开(公告)号：US20240096451A1

公开(公告)日：2024-03-21

申请号：US18454312

申请日：2023-08-23

申请人： Genomic Health, Inc.

发明人： Wayne Cowens ,  Steven SHAK ,  Audrey GODDARD ,  Dejan KNEZEVIC ,  Joffre Baker ,  Michael C. Kiefer ,  Tara MADDALA ,  Frederick L. Baehner

IPC分类号： G16B99/00 ,  G01N33/574 ,  G06N7/01 ,  G16B25/10

CPC分类号： G16B99/00 ,  G01N33/57438 ,  G06N7/01 ,  G16B25/10 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.

公开(公告)号：US10892038B2

公开(公告)日：2021-01-12

申请号：US15368979

申请日：2016-12-05

申请人： GENOMIC HEALTH, INC.

发明人： Wayne Cowens ,  Steven Shak ,  Audrey Goddard ,  Dejan Knezevic ,  Joffre Baker ,  Michael C. Kiefer ,  Tara Maddala ,  Frederick L. Baehner

IPC分类号： G01N33/574 ,  G16B99/00 ,  G06N7/00

摘要： The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.

公开(公告)号：US10260104B2

公开(公告)日：2019-04-16

申请号：US14887605

申请日：2015-10-20

申请人： GENOMIC HEALTH, INC.

发明人： Steven Shak ,  Frederick L. Baehner ,  Tara Maddala ,  Mark Lee ,  Robert J. Pelham ,  Wayne Cowens ,  Diana Cherbavaz ,  Michael C. Kiefer ,  Michael Crager ,  Audrey Goddard ,  Joffre B. Baker

IPC分类号： G06F19/00 ,  C12Q1/6886

摘要： The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.